REPLIGEN GOES FROM GAIN TO LOSS FOR QUARTERRepligen Corp. (NASDAQ:RGEN) of Cambridge, Mass., attributeda decrease in net income in the third quarter in part toexpenses related to a new anti-inflammatory program toaugment its retroviral and cancer project. Chief ExecutiveOfficer Sandford D. Smith said, "Increased expenses for thethird quarter are directly attributable to Repligen's continueddrive to extend its health care portfolio and the costs of plateletfactor-4 product scale-up for clinical evaluation."

Third quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,489 4,062 -39Net income (loss) (1,580) 128 n/aNet income per share (loss) (.17) .02 n/aOutstanding shares 9,237 7,748 +19

VENTREX REDUCES QUARTERLY LOSS

Ventrex Laboratories Inc. (NASDAQ/NMS:VTRX) of Portland,Maine, President John Lincoln said gross margins increasedfrom 48 percent in the first quarter last year to 52 percent forthe first quarter this year. Sales increases in allergy,bioreagents and coated tube RIA products were offset by anequal declines Ventrescreen (primarily Strep A) and theformer Cambridge RIA kit products.

First quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,560 3,601 - 1Net income (loss) (19) (245) +92Net income per share (loss) 0 (.02) n/a

HYCOR'S NET DOWN SLIGHTLY

Hycor Biomedical Inc. (NASDAQ:HYBD) of Garden Grove, Calif.,Chief Executive Officer Richard D. Hamill said the company'sfinancial results were on target and reflect the costs ofinvesting in the product launch of accuPinch on-site drug-abuse tests.

Fourth quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,067 2,759 +11Net income (loss) 525 497 +6Net income per share (loss) .08 .08 n/cOutstanding shares 6,119 6,079 neg.

Fiscal year ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $10,596 9,616 +10Net income (loss) 944 1,134 -17Net income per share (loss) .15 .19 -21Outstanding shares 6,188 5,984 +3

(c) 1997 American Health Consultants. All rights reserved.

No Comments